Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

Lantheus (LNTH) reported receiving a second request from the FTC regarding its $8B sale to Curium. Both companies were asked for additional information by the FTC on Wednesday.

Lantheus and Curium received FTC Second Requests on October 21, extending the HSR waiting period. The companies expect to respond promptly and continue to anticipate closing the merger in the first half of 2027, subject to regulatory approvals.

JPMorgan Chase and Jefferies are leading a $4.25 billion financing deal for Lantheus Holdings. Citigroup adjusted its price target for JPMorgan to $350 from $360.

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw

Lantheus (NASDAQ: LNTH) announced CMS granted Transitional Pass-Through payment status for PYLARIFY® TruVu (piflufolastat F 18), effective October 1, 2026. This designation enables separate reimbursement in hospital outpatient settings, supporting access to the diagnostic radiopharmaceutical for Medicare beneficiaries. PYLARIFY TruVu is a new formulation of Lantheus’ PSMA-targeted PET imaging agent for prostate cancer, with a permanent HCPCS code assigned for billing and reimbursement.

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw